Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XILO-FIST: Allopurinol for outcomes after ischaemic stroke
NCT02122718Phase 4Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2014
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of allopurinol in ischemic stroke, transient ischaemic attack (TIA), Dementia and 1 more, sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: White matter hyper-intensities progression rate at 2 years. Started May 2014; status: completed.
02
Drugs
allopurinol
03
Conditions
ischemic stroketransient ischaemic attack (TIA)DementiaNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT02122718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122718.